| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
E-mail contact: s.heeneman@path.unimaas.nl
Extracellular matrix (ECM) remodeling is one of the underlying mechanisms in cardiovascular diseases. Cathepsin cysteine proteases have a central role in ECM remodeling and have been implicated in the development and progression of cardiovascular diseases. Cathepsins also show differential expression in various stages of atherosclerosis, and in vivo knockout studies revealed that deficiency of cathepsin K or S reduces atherosclerosis. Furthermore, cathepsins are involved in lipid metabolism. Cathepsins have the capability to degrade low-density lipoprotein and reduce cholesterol efflux from macrophages, aggravating foam cell formation. Although expression studies also demonstrated differential expression of cathepsins in cardiovascular diseases like aneurysm formation, neointima formation, and neovascularization, in vivo studies to define the exact role of cathepsins in these processes are lacking. Evaluation of the feasibility of cathepsins as a diagnostic tool revealed that serum levels of cathepsins L and S seem to be promising as biomarkers in the diagnosis of atherosclerosis, whereas cathepsin B shows potential as an imaging tool. Furthermore, cathepsin K and S inhibitors showed effectiveness in (pre) clinical evaluation for the treatment of osteoporosis and osteoarthritis, suggesting that cathepsin inhibitors may also have therapeutic effects for the treatment of atherosclerosis.--Lutgens, S. P. M., Cleutjens;, K. B. J. M., Daemen, M. J. A. P., Heeneman, S. Cathepsin cysteine proteases in cardiovascular disease.
This article has been cited by other articles:
|
|
 |
|
  A. Saratzis, G. D. Kitas, N. Saratzis, and N. Melas Can Statins Suppress the Development of Abdominal Aortic Aneurysms? A Review of the Current Evidence Angiology, February 1, 2010; 61(2): 137 - 144. [Abstract] [PDF]
|
|
|
|
 |
|
 E. M. Johnson, J. D. Doyle, J. D. Wetzel, R. P. McClung, N. Katunuma, J. D. Chappell, M. K. Washington, and T. S. Dermody Genetic and Pharmacologic Alteration of Cathepsin Expression Influences Reovirus Pathogenesis J. Virol., October 1, 2009; 83(19): 9630 - 9640. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Brizzola, M. de Eguileor, T. Brevini, A. Grimaldi, T. Congiu, P. Neuenschwander, and F. Acocella Morphologic features of biocompatibility and neoangiogenesis onto a biodegradable tracheal prosthesis in an animal model Interactive CardioVascular and Thoracic Surgery, June 1, 2009; 8(6): 610 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zhang, R. Sheng, and Z. Qin The lysosome and neurodegenerative diseases Acta Biochim Biophys Sin, June 1, 2009; 41(6): 437 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Hofnagel and H. Robenek Cathepsin K: boon or bale for atherosclerotic plaque stability? Cardiovasc Res, February 1, 2009; 81(2): 242 - 243. [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Jaffer, C. Vinegoni, M. C. John, E. Aikawa, H. K. Gold, A. V. Finn, V. Ntziachristos, P. Libby, and R. Weissleder Real-Time Catheter Molecular Sensing of Inflammation in Proteolytically Active Atherosclerosis Circulation, October 28, 2008; 118(18): 1802 - 1809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-F. Cailhier, I. Sirois, P. Laplante, S. Lepage, M.-A. Raymond, N. Brassard, A. Prat, R. V. Iozzo, A. V. Pshezhetsky, and M.-J. Hebert Caspase-3 Activation Triggers Extracellular Cathepsin L Release and Endorepellin Proteolysis J. Biol. Chem., October 3, 2008; 283(40): 27220 - 27229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Elkaim, S. Werner, L. Kocgozlu, and H. Tenenbaum P. gingivalis Regulates the Expression of Cathepsin B and Cystatin C Journal of Dental Research, October 1, 2008; 87(10): 932 - 936. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
